Misonix Incorporated And SIAD Healthcare Renew Distribution Agreement For Italy

FARMINGDALE, N.Y., June 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with SIAD Healthcare, based in Milano, Italy, for the distribution of the SonaStar® Ultrasonic Surgical Aspiration System, the BoneScalpel Ultrasonic Bone Cutting System and the SonicOne® Ultrasonic Wound Cleansing and Debridement System. The agreement provides SIAD with the right to sell throughout Italy, San Marino and Vatican City. Included in the agreement are annual minimum purchase requirements. This continues a previous, successful 3-year distribution partnership.

As a result of their divisional organization, SIAD has proven their ability to successfully market Misonix products to a wide variety of surgical disciplines, including neurosurgery, skull-based surgery, spine surgery and wound debridement, demonstrated by placing double digit quantities of the SonaStar, BoneScalpel and SonicOne into Italian hospitals. They are recognized for their commitment to clinical education and have developed an excellent reputation for service after the sale.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. OsteoSculpt bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

“We are exceptionally pleased to continue our mutually rewarding business alliance with SIAD. We have great respect for their professional management and attention to our products, current and future. They have impressive long-term relationships with key physicians throughout Italy in spine, craniomaxillofacial (CMF) and neuro surgeries, as well as wound care. Their past success with introducing new technologies to their market speaks for itself,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “We are particularly pleased that they are selling our three lead products throughout Italy.”

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.